Print

GlycoMimetics, Inc. Announces Publication in Nature Medicine of Preclinical Data for Its GMI-1070 Drug Candidate  
10/22/2012 9:43:08 AM

GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, announced today that preclinical data related to its lead drug candidate, GMI-1070, has been published in the current issue of Nature Medicine. The paper describes a new function of E-selectin related to the cycling of hematopoetic stem cells in the bone marrow. Hematopoetic stem cells are multipotent stem cells that give rise to many blood cell types. In the paper, authors highlight how genetically knocking-out E-selectin, or treatment with GMI-1070, protects these stem cells from some of the toxic effects of chemotherapy.
//-->